A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK3102 in Obese Subjects and in Patients With Type 2 Diabetes.
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Omarigliptin (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- 23 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 26 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History